Back to top
more

Baxter International (BAX)

(Real Time Quote from BATS)

$23.67 USD

23.67
1,326,350

+0.13 (0.55%)

Updated Aug 8, 2025 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Zacks Equity Research

Phibro Animal (PAHC) Q3 Earnings Beat, Sales Improve Y/Y

by Zacks Equity Research

Phibro (PAHC) witnesses year-over-year improvement across all segments in Q3.

    Zacks Equity Research

    DaVita (DVA) Beats Q1 Earnings Estimates, Reiterates View

    by Zacks Equity Research

    Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q1.

      Zacks Equity Research

      PetMed (PETS) Q4 Earnings Top Estimates, Reorder Sales Solid

      by Zacks Equity Research

      PetMed (PETS) Q4 sales rise on increased reorders

        Zacks Equity Research

        Bruker (BRKR) Q1 Earnings & Revenues Beat, Margins Expand

        by Zacks Equity Research

        Bruker's (BRKR) Q1 benefits from improved European revenues, rising year over year in high-single digits.

          Zacks Equity Research

          ABIOMED (ABMD) Earnings Beat Estimates in Q4, View Impressive

          by Zacks Equity Research

          ABIOMED (ABMD) gains on surging Impella revenues, number of regulatory approvals.

            Zacks Equity Research

            Surmodics (SRDX) Beats on Q2 Earnings & Revenues, Raises View

            by Zacks Equity Research

            Surmodics' (SRDX) second-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

              Zacks Equity Research

              DENTSPLY (XRAY) Beats Q1 Earnings Estimates, Lowers View

              by Zacks Equity Research

              Strong performance in Europe and Rest of World boosts DENTAPLY's (XRAY) performance in Q1. However, a lowered guidance indicates looming concerns.

                Zacks Equity Research

                IDEXX Laboratories (IDXX) Earnings, Revenues Rise in Q1

                by Zacks Equity Research

                IDEXX (IDXX) rides on strength in CAG business in Q1. A raised EPS guidance buoys optimism.

                  Zacks Equity Research

                  QIAGEN (QGEN) Beats Earnings, Revenue Estimates in Q1

                  by Zacks Equity Research

                  QIAGEN's (QGEN) year-over-year growth in Q1 revenues is encouraging. Expansion in operating margin buoys optimism.

                    Zacks Equity Research

                    Integer Holdings (ITGR) Q1 Earnings Miss, View Impressive

                    by Zacks Equity Research

                    Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises hopes.

                      Zacks Equity Research

                      Allscripts (MDRX) Q1 Earnings & Revenues Lag, Bookings Rise

                      by Zacks Equity Research

                      Allscripts (MDRX) witnesses strong segmental performances; a solid guidance encourages.

                        Zacks Equity Research

                        DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View

                        by Zacks Equity Research

                        Solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues drive DexCom's (DXCM) Q1 results.

                          Zacks Equity Research

                          Cardinal Health (CAH) Misses on Q3 Earnings, Lowers '18 View

                          by Zacks Equity Research

                          Cardinal Health (CAH) saw a tepid Q3 owing to declining profits at the Pharmaceutical unit despite a decent performance by the Medical segment.

                            Zacks Equity Research

                            Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Low

                            by Zacks Equity Research

                            Within Genomic Health's (GHDX) prostate cancer business, strengthened NCCN prostate cancer guidelines and additional new data increase private coverage for the Oncotype DX GPS test.

                              Zacks Equity Research

                              Cardiovascular Systems (CSII) Q3 Earnings Top, Revenues Meet

                              by Zacks Equity Research

                              Cardiovascular Systems' (CSII) peripheral device revenues continue to gain from a consistent strength in hospital setting.

                                Zacks Equity Research

                                Express Scripts (ESRX) Q1 Earnings Top, Patient Claims Fall

                                by Zacks Equity Research

                                Express Scripts (ESRX) witnesses year-over-year declines in patient claims in Q1, thanks to the loss of certain public sector clients.

                                  Zacks Equity Research

                                  Pacific Biosciences (PACB) Loss Wider Than Expected in Q1

                                  by Zacks Equity Research

                                  Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.

                                    Zacks Equity Research

                                    Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View

                                    by Zacks Equity Research

                                    Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.

                                      Zacks Equity Research

                                      Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top

                                      by Zacks Equity Research

                                      Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.

                                        Zacks Equity Research

                                        CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow

                                        by Zacks Equity Research

                                        CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.

                                          Zacks Equity Research

                                          AmerisourceBergen (ABC) Q2 Earnings Top, FY18 View Solid

                                          by Zacks Equity Research

                                          AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and World Courier business in Q2.

                                            Zacks Equity Research

                                            NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line

                                            by Zacks Equity Research

                                            NuVasive (NUVA) gains on continued growth in international business along with strong case volume growth in the U.S. Hardware business in Q1.

                                              Zacks Equity Research

                                              Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top

                                              by Zacks Equity Research

                                              Radixact System and major software overhaul drive Accuray (ARAY) in Q3.

                                                Zacks Equity Research

                                                Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View

                                                by Zacks Equity Research

                                                Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.

                                                  Zacks Equity Research

                                                  athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q1

                                                  by Zacks Equity Research

                                                  Revenues in Business and Services along with a strong client base boost athenahealth's (ATHN) Q1 earnings.